Elanco Animal Health Incorporated Overview
Pro stress-test →Elanco Animal Health Incorporated is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. The company achieved its 10th consecutive quarter of underlying growth in Q4 2025, demonstrating strong operational momentum with an innovation-led growth strategy.
Strategic Profile
Pro stress-test →Elanco is executing on a multi-wave blockbuster pipeline strategy with over 10 major innovation projects with blockbuster potential and 5-6 expected blockbuster approvals between 2026 and 2031. The company is raising its outlook for the innovation basket to $1.15 billion in 2026, while improving net leverage ratio faster than planned, targeting under 3x by 2027.
Competitive Landscape
Pro stress-test →Elanco competes in the global animal health market against major pharmaceutical and animal health companies. Key competitors include Zoetis, Merck Animal Health, and Boehringer Ingelheim's animal health division. Elanco's differentiation is driven by its blockbuster innovation pipeline, global scale across farm animals and companion pets, and strategic focus on high-growth therapeutic areas.
Industry Context
Elanco Animal Health Incorporated operates in Animal health pharmaceuticals and biologics.
Key facts
Founded: 2018 · Headquarters: Indianapolis, IN, US · Revenue: $5.0-5.1B (FY2026 guidance)